Skip to main content

Carl Bernstein about Bill Clinton's first term

Back in 2007, as Hillary Clinton, Barack Obama, Joe Biden and several others were maneuvering in anticipation of the Democratic Party's upcoming presidential primary campaign, Alfred Knopf brought out a book by Pulitzer Prize winner Carl Bernstein, A WOMAN IN CHARGE, about Hillary's life.

Here's a fascinating passage, describing the inner workings of the Clinton administration in early 1994.

"Many of Bill Clinton's top aides felt that Hillary was impatient when listening to their criticisms [and that Ira Magaziner was acting as her bulldog]....Magaziner infuriated the president's aides when they learned he was meeting privately with the Clintons in the White House residence and urging them to make important decisions without consulting either the [health care] task force or the economic team. Hillary's stature with Bentsen and even her old friend Shalala was deteriorating.

"The president seemed caught between his wife and his advisers. More often than not, he would mediate disputes between them saying 'Let's revisit this.' In fact, a new dynamic in the Clinton partnership was developing: for the first time, he seemed inclined to placate Hillary, and make decisions he strongly believed were against his better instincts. That was a mistake."

It was a mistake because, on Bernstein's account, Bill's increasing disposition to placate Hillary led to the defeat of that administration's health care proposal, which became too exclusively the Hillary/Ira show, and to the Republican takeover of Congress that November.

As the world looks forward to another HR Clinton presidential campaign, this strikes me as worthy of contemplation.



Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

England as a Raft?

In a lecture delivered in 1880, William James asked rhetorically, "Would England ... be the drifting raft she is now in European affairs if a Frederic the Great had inherited her throne instead of a Victoria, and if Messrs Bentham, Mill, Cobden, and Bright had all been born in Prussia?"

Beneath that, in a collection of such lectures later published under James' direction, was placed the footnote, "The reader will remember when this was written."

The suggestion of the bit about Bentham, Mill, etc. is that the utilitarians as a school helped render England ineffective as a European power, a drifting raft.

The footnote was added in 1897. So either James is suggesting that the baleful influence of Bentham, Mill etc wore off in the meantime or that he had over-estimated it.

Let's unpack this a bit.  What was happening in the period before 1880 that made England seem a drifting raft in European affairs, to a friendly though foreign observer (to the older brother…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…